Diabetic polyneuropathy: a current algorithm for patient management
https://doi.org/10.14412/2074-2711-2019-2-100-105
Abstract
Diabetic polyneuropathy (DPN) is the most common chronic complication of diabetes mellitus and can develop just at the prediabetes stage. As DPN progresses and, in the absence of its adequate treatment, leads to worse quality of life and its shorter expectancy in patients. The paper discusses current clinical guidelines for the examination and management of patients with DPN, diagnostic methods, and pathogenetic treatment of this disease.
About the Authors
L. T. Akhmedzhanova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
11, Rossolimo St., Build. 1, Moscow 119021
A. N. Barinov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
Aleksey Nikolaevich Barinov
11, Rossolimo St., Build. 1, Moscow 119021
O. A. Solokha
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
11, Rossolimo St., Build. 1, Moscow 119021
I. A. Strokov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
11, Rossolimo St., Build. 1, Moscow 119021
O. B. Doronina
Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
52, Krasnyi Prospect, Novosibirsk 630091
K. S. Doronina
Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
52, Krasnyi Prospect, Novosibirsk 630091
A. S. Rozhdestvensky
Omsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
12, Lenin St., Omsk 644099
References
1. Dedov II, Shestakova MV, Galstyan GR. Prevalence of type 2 diabetes in the adult population of Russia (NATION study). Sakharnyi diabet. 2016;19(2):104-12. (In Russ.).
2. Dedov II, Kalashnikova MF, Belousov DYu. Analysis of the cost of type 2 diabetes in the Russian Federation: results of the Russian multicenter observational pharmacoepidemiological study Foresight-SD2.2017. Sakharnyi diabet. 2017;20(6):403-19. (In Russ.).
3. Barinov AN. Vegetative neuropathy in diabetes mellitus and metabolic syndrome: clinical manifestations, diagnosis and treatment. Effektivnaya farmakoterapiya. 2017;(2):40-52. (In Russ.).
4. Maffi P, Secchi A. The Burden of Diabetes: Emerging Data. Dev Ophthalmol. 2017;60:1-5. doi: 10.1159/000459641. Epub 2017 Apr 20.
5. Ziegler D, Rathmann W, Dickhaus T, et al; KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009 Mar;10(2):393-400. doi: 10.1111/j.1526-4637.2008.00555.x. Epub 2009 Jan 16.
6. Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015 May;38(5):793-800. doi: 10.2337/dc14-2585. Epub 2015 Feb 9.
7. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: a Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042.
8. Llewelyn JG, Tomlinson DR, Thomas PK. Diabetic neuropathies. Vol. 2. Philadelphia: Elsevier Sounders; 2005. P. 1951-91.
9. Fedorova OS, Gur'eva IV, Strokov IA, Akhmedzhanova LT. The role of diabetic distal polyneuropathy in imbalance in patients with diabetes mellitus (literature review). Endokrinologiya. 2013;(1):43-50. (In Russ.).
10. Sloan G, Shillo P,Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes Res Clin Pract. 2018 Oct;144:177-191. doi: 10.1016/j.diabres.2018.08.020. Epub 2018 Sep 7.
11. Blesneac I, Themistocleous AC, Fratter C. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain. 2018 Mar; 159(3):469-480. doi: 10.1097/j.pain.0000000000001116.
12. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011 Oct;27(7):639-53. doi: 10.1002/dmrr.1239.
13. Knowler W, Fowler S, Hamman R, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702): 1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29.
14. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 Jun;29(6):1294-9.
15. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev Diabet Stud. 2015 SpringSummer;12(1-2):48-62. doi: 10.1900/RDS.2015.12.48. Epub 2015 Aug 10.
16. Akhmedzhanova LT, Barinov AN, Strokov IA. Diabetic and nondiabetic polyneuropathy in patients with diabetes mellitus. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018; 118(4):113-21. (In Russ.).
17. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxydant alpha-lypoic acid. (ALADIN study group). Diabetologia. 1995 Dec;38(12):1425-33.
18. Ziegler D, Ametov A, Barinov A, et. al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy the SYDNEY 2 trial. Diabetes Care. 2006 Nov; 29(11):2365-70.
19. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2): 114-21.
20. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10): 2285-93. doi: 10.2337/dc10-1303.
21. Stracke H, GausW, Achenbach U, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomized, doubleblind, placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes. 2008 Nov;116(10):600-5. doi: 10.1055/s-2008-1065351. Epub 2008 May 13.
22. Mimenza AA, Aguilar NS. Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. J Diabetes Res. 2016;2016:4078695. doi: 10.1155/2016/4078695. Epub 2016 Jan 17.
23. Strokov IA, Akhmedzhanova LT, Barinov AN, et al. Pathogenetic therapy of diabetic polyneuropathy with alpha-lipoic acid from the point of view of evidence-based medicine. Effektivnaya farmakoterapiya. 2019;(1):32-40. (In Russ.).
Review
For citations:
Akhmedzhanova LT, Barinov AN, Solokha OA, Strokov IA, Doronina OB, Doronina KS, Rozhdestvensky AS. Diabetic polyneuropathy: a current algorithm for patient management. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):100-105. (In Russ.) https://doi.org/10.14412/2074-2711-2019-2-100-105
Views:
728
Email this article 